NEW YORK – Mammoth Biosciences is taking a lead role in a US government-funded, public-private effort to develop multi-pathogen detection platforms based on CRISPR gene editing technology, demonstrating the firm's CRISPR enzyme detection and engineering prowess and underscoring the general flexibility of the approach for infectious disease diagnostics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.